Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Remifentanil on Propofol-Induced Burst Suppression
NCT06237101Recruiting
- Sponsor
- Universidad de Chile
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of remifentanil in general anesthesia (2 arms), sponsored by Universidad de Chile. Primary endpoint: Propofol estimated concentration by Marsh pharmacological model, which generates burst suppression at 10 minutes. Started Mar 2024; status: recruiting.
02
Drugs
remifentanil
03
Conditions
general anesthesia
Beyond the preview
Go deeper on NCT06237101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237101.